Carbón activado

Activated Charcoal: A Comprehensive Reference

1. Identity: Chemical Nature, Sources, and Common Forms

1.1 Chemical and Physical Identity

Activated charcoal, also known as activated carbon, is a form of carbon that has been processed or "activated" to make it extremely porous, such that it has a very large surface area and pore volume available for adsorption or chemical reactions. Activated charcoal is biologically inert. Its chemical formula is simply elemental carbon (C), though the arrangement of that carbon — not its atomic composition — defines its extraordinary functional properties. Unlike graphite or diamond, activated charcoal possesses a highly disordered, amorphous microcrystalline structure.

Activated charcoal possesses a highly porous structure and thus a very large surface area per mass unit, typically 500 to 1500 m²/g. The size of the active surface area varies according to the raw material used and the degree of activation of the carbon. Due to the porous structure, 99% of the adsorption area of activated charcoal exists in the internal parts of the charcoal. Because it is so porous on a microscopic scale, activated carbon has a surface area of over 3,000 square metres per gram, as determined by gas absorption.

The structure of activated charcoal comprises micro-, meso-, and macropores; their combined area indicates the quantity of particles that the activated charcoal is able to adsorb. The size of the pores indicates the size of the particles that can be adsorbed to the surface of the activated charcoal. Surface area is measured using the Brunauer–Emmett–Teller (BET) method, typically employing nitrogen gas adsorption at low temperatures.

1.2 Natural Sources and Raw Materials

Activated charcoal is a chemically inert form of carbon prepared by pyrolysis of carbonaceous matter — including coconut, pulverised peat, or sawdust — at 600–900°C in a kiln without air. The structure and most important properties of activated carbons depend on the type of raw material used to produce them, pre-treatment of the raw material, the conditions prevailing during the entire production process, and the final processing stages. Nearly any raw material containing carbon can be used for the production of activated carbons. Common pharmaceutical-grade sources include coconut shell, wood (hardwood and softwood), peat, and coal, each yielding charcoals with differing pore size distributions suited to different applications.

1.3 Activation Methods

Two principal activation pathways are employed in manufacturing:

• Physical (steam) activation: The carbonaceous material is prepared by pyrolysis of carbonaceous matter at 600–900°C in a kiln without air, then exposed to steam or CO₂ at 600–700°C, which forms an internal maze of pores.
• Chemical activation: In the dry process, a powdered activating agent is mixed directly with the raw material, after which the activation process is carried out. In the wet/impregnation process, the raw material — mainly biomass — is added to a water solution containing an activating agent. This mixture is then stirred continuously until the chemical is completely dissolved, and the suspension is dried before heat treatment. Zinc chloride (ZnCl₂) is a very effective activator that enables the creation of a developed pore structure while preventing the formation of tar and other undesirable products that can block previously developed pores.

1.4 Common Preparations and Dosage Forms

Formulations have been attempted to increase the palatability of activated charcoal, which is black and has a gritty texture. Ready-to-use aqueous suspensions of activated charcoal are available in 15 g, 25 g, and 50 g doses, as well as formulations premixed with sorbitol. If activated charcoal is not premixed, a slurry can be made with activated charcoal in a 1:8 ratio of activated charcoal to a suitable liquid such as water, cola, or flavored syrups.

Beyond clinical oral suspensions, activated charcoal appears commercially as fine black powders, capsules, and tablets intended for dietary supplement use; as ingredients in toothpastes and dental products; as topical wound dressings; and as a constituent of water and air filtration systems. The pharmaceutical and supplement markets represent distinct regulatory and quality contexts, with pharmaceutical-grade preparations held to pharmacopeial standards not applicable to most consumer supplement products.

2. Traditional and Historical Use

2.1 Ancient Egypt and Early Antiquity (c. 3750–400 BCE)

The use of charcoal as a medicinal product can be traced back to Egypt in 1500 BC, where it was used to neutralise bad odours from wounds. The Egyptians eventually discovered that charcoal had antibacterial properties when they realized that charred wooden posts didn't rot when placed into the Nile for the purpose of building docks. This discovery led to continued use of charcoal in Egyptian medical, embalming, and burial practices.

By 400 BC, the Phoenicians used charcoal to improve the taste of water stored on ships by containing the water in charred barrels, indicating that an understanding of charcoal's ability to adsorb undesirable chemicals was present by this time.

2.2 Classical Greek and Roman Medicine

In the 4th century BC, the Greek physician Hippocrates also used activated charcoal to treat a variety of ailments, including food poisoning and related diseases. Several early, groundbreaking physicians of this time, such as Hippocrates, used charcoal to treat a variety of ailments such as epilepsy (a seizure disorder), iron deficiencies, dizziness, and even bacterial diseases like anthrax.

In the 1st century AD, the Roman physician Pliny the Elder also wrote about the medicinal uses of activated charcoal. Claudius Galen, a pioneering and famous physician and scientist in the second century, regularly referenced his use of charcoal to treat disease.

2.3 Medieval and Early Modern Periods

Charcoal continued to be a strong force in the 19th century, especially in medicine. It was used for poultices, sloughing ulcers, and treating gangrenous sores. Charcoal biscuits were sold in England starting in the early 19th century, originally as a remedy for flatulence and stomach trouble.

2.4 18th-Century Scientific Characterization

The adsorption skills of activated carbon were discovered in the late 18th century: in 1773, Carl Wilhelm Scheele discovered the adsorptive power of charcoal in the liquid phase. He found that charcoal could be used to remove impurities from water, such as bad taste and odors. In the following years, in 1785, Johann Tobias Lowitz studied the industrial application of charcoal in various aqueous solutions for the removal of bad taste and odors from water, including dye removal and decolorization.

German physicist Heinrich Kayser coined the term "adsorption" to describe charcoal's ability to uptake gases in 1881. After the activated carbon process was developed around 1820, it became noted in medical journals as an antidote for poison and a treatment for intestinal disorders. The adsorbent property of charcoal was first documented in 1791, and the use of charcoal in medicine as an antidote for poisoning started in the 1830s.

2.5 Early Clinical Demonstrations (19th Century)

In 1883, French chemist Gabriel Bertrand, in an effort to prove charcoal's worth as a poison treatment, swallowed arsenic mixed with charcoal. Others followed suit and performed the same demonstration. These dramatic self-experiments established charcoal's antidotal properties in the popular and scientific imagination well before controlled clinical trials existed.

2.6 Listing on the WHO Essential Medicines List

While charcoal has been used since ancient times for poisonings, activated charcoal has been used since the 1900s. It is on the World Health Organization's List of Essential Medicines.

3. Key Constituents and Active Compounds

Activated charcoal is not a botanical extract containing discrete phytochemical constituents. Its identity is structural rather than compositional. The "active ingredient" is the carbon matrix itself, whose functional potency is determined by physical properties rather than chemical species.

3.1 Elemental Composition

Activated charcoal consists almost entirely of elemental carbon arranged in disordered graphite-like microplatelets. The matrix may contain trace amounts of oxygen, hydrogen, sulfur, and ash (mineral residues from the source material), the proportions of which vary by feedstock and activation method. Due to the porous structure, 99% of the adsorption area of activated charcoal exists in the internal parts of the charcoal.

3.2 Structural Determinants of Activity

The critical functional properties are:

• Total surface area — typically 500–1500 m²/g for pharmaceutical grades, measurable by the BET nitrogen adsorption method.
• Pore size distribution — micropores (<2 nm), mesopores (2–50 nm), and macropores (>50 nm). The pore size and surface morphology of activated charcoal defines the types of molecules that could be adsorbed onto it, as surface morphology plays a significant role in determining the surface availability and areas of adsorption.
• Surface chemistry — functional groups on the carbon surface can engage in hydrogen bonding and π–π (pi–pi stacking) interactions with aromatic toxin molecules.

The specific surface area of activated carbons is not always proportional to adsorption capacity due to the pore diameter often being smaller than the diameter of the adsorbate molecule, or the shape of the pores not allowing adsorbate molecules to penetrate into the micropores. Therefore, the proper selection of activated carbons for specific applications should consider the size and shapes of the micropores, not just their specific surface areas and pore volumes.

4. Established Mechanisms of Action

4.1 Adsorption (Primary Mechanism)

Activated charcoal acts primarily through adsorption, binding a wide range of drugs and toxins in the gastrointestinal (GI) tract and preventing their absorption into the bloodstream. It is essential to distinguish adsorption from absorption: adsorption, not to be confused with absorption, is a process where atoms or molecules adhere to a surface.

Activated charcoal's extensive surface area allows it to adsorb drugs and toxins, reducing their GI absorption and systemic toxicity. The process is rapid and most effective when administered soon after ingestion, ideally within the first hour. Adsorption is a physical process, primarily involving van der Waals forces and, for some substances, π–π interactions and hydrogen bonding.

When in the presence of some poisons, activated charcoal adsorbs the chemical onto its surface, rendering it unable to interact with the body. This is possible due to its high surface area compared to its volume.

4.2 Interruption of Enterohepatic Recirculation (Secondary Mechanism)

Multiple-dose activated charcoal (MDAC) can enhance the elimination of certain drugs by interrupting enterohepatic and entero-enteric recirculation. Activated charcoal both reduces primary drug absorption and enhances drug elimination. However, the two mechanisms of action overlap and are indistinguishable from each other.

A meta-analysis published in PubMed quantified this effect: all but one of 21 included studies used multiple-dose activated charcoal (MDAC). MDAC reduced the median half-life of the intravenously administered study drugs by 45.7% (interquartile range: 15.3%–51.3%).

4.3 Substances Not Adsorbed

Activated charcoal is ineffective for certain substances, including acids, bases, alcohols, metals, and some inorganic salts. Its efficacy depends on the timing, dose, and nature of the ingested substance. It is not effective for a number of poisonings including: strong acids or bases, iron, lithium, arsenic, methanol, ethanol or ethylene glycol.

4.4 Systemic Bioavailability

No significant toxicity from activated charcoal exists as it is not systemically absorbed; however, adverse effects from the administration, such as emesis, aspiration, and bowel obstruction, can occur. As activated charcoal remains inert within the GI tract, no therapeutic index for systemic absorption exists.

5. Scientific Evidence by Area of Use

5.1 Acute Poisoning and Drug Overdose

Overview of Evidence

The use of activated charcoal in poisoning remains both a pillar of modern toxicology and a source of debate. Activated charcoal adsorbs many noxious substances — medical drugs, phytotoxins, and poisonous chemicals — onto its surface, preventing their absorption from the gastrointestinal tract.

Single-Dose Activated Charcoal (SDAC)

Activated charcoal is a gastrointestinal adsorbent used in the management of acute oral poisoning and overdose. Activated charcoal binds to several drugs and toxins in the gastrointestinal tract, thereby reducing systemic absorption and limiting toxicity. Activated charcoal is most efficacious when given within one hour of ingestion of the toxin.

Following the publication of the joint position statements on the use of single-dose and multiple-dose activated charcoal by the American Academy of Clinical Toxicology and the European Association of Poison Centres and Clinical Toxicologists, the routine use of activated charcoal declined. Over subsequent years, many new pharmaceuticals became available in modified or alternative-release formulations and additional data on gastric emptying time in poisoning was published, challenging previous assumptions about absorption kinetics.

Systematic Review and Meta-analysis Evidence

A systematic review and meta-analysis (searching PubMed, ClinicalTrials.gov, Cochrane CENTRAL, and Scopus through December 2023) specifically evaluating RCTs in poisoning management found: thirteen RCTs involving 5,059 patients were included in the study. Meta-analysis revealed a significant decrease in drug plasma concentration (P = 0.002) and AUC (P < 0.0001) favouring AC intervention. No significant differences were observed in time to peak serum drug level (P = 0.59) and hospital stay (P = 0.34). Safety analysis showed no significant difference in mortality (P = 0.25), whereas cardiac arrhythmia incidence was significantly lower with AC (P = 0.004).

A 2021 systematic review from the Clinical Toxicology Recommendations Collaborative, which searched multiple databases from inception to December 31, 2019, with no language limitations, evaluated outcomes across 85 full-text articles involving 29,217 patient samples. Combination therapy with gastric lavage and activated charcoal is widely used, although clinical studies to date have not provided evidence of additional efficacy compared with the use of activated charcoal alone. There are also doubts regarding the efficacy of activated charcoal when administered more than 1 hour after the overdose.

When administered soon after ingestion, it can significantly reduce the absorption of many drugs and toxins. However, evidence demonstrating improvement in patient-oriented outcomes remains limited, and activated charcoal administration carries potential risks, including aspiration and gastrointestinal complications.

Multi-Dose Activated Charcoal (MDAC)

MDAC refers to the administration of 2 or more sequential doses of activated charcoal to enhance the elimination of an ingested toxin. MDAC appears to reduce ongoing absorption of toxin remaining in the gastrointestinal tract and enhance elimination through enterohepatic or enteroenteric recirculation. Although the quality of clinical data is limited, MDAC is generally considered beneficial for potentially life-threatening ingestions of carbamazepine, dapsone, phenobarbital, quinine, and theophylline.

A published study using phenobarbital administered intravenously demonstrated that MDAC at a dose of 50 g initial dose, then 25 g every 4 hours, significantly reduced the mean half-life (19 h vs. 148 h) and increased total body clearance compared to no MDAC, and was more efficacious than urinary alkalinization for both endpoints.

Limitations and Evidence Gaps

The overall evidence base for mortality reduction and patient-centered outcomes from activated charcoal in poisoning remains limited. A large randomized controlled trial of acute self-poisoning from agricultural pesticides and yellow oleander seeds found that the administration of activated carbon did not affect survival rates. This highlights that efficacy is substantially dependent on the physicochemical properties of the ingested substance, the timing of administration, and the dose ingested relative to the charcoal dose provided.

5.2 Chronic Kidney Disease (CKD) and Uremic Toxins

A growing area of clinical investigation concerns the use of oral activated charcoal as an intestinal adsorbent to reduce the accumulation of uremic toxins in CKD. One of the complications of chronic kidney disease is impaired intestinal barrier function, which may allow harmful products such as urea to enter the bloodstream and cause systemic inflammation.

A 2023 randomized clinical trial conducted at the Dialysis Center of al-Diwaniyah Medical Hospital enrolled patients with end-stage renal disease on regular hemodialysis: the study was a randomized clinical trial. Eighty-two patients with ESRD on regular hemodialysis were enrolled, with 15 patients receiving oral supplementation with activated charcoal in addition to standard care and 13 patients receiving only standard care. Blood samples were collected at baseline and after eight weeks, and several biomarkers were measured, including estimated glomerular filtration rate (eGFR), creatinine, urea, phosphorus, albumin, and indoxyl sulfate. The results showed a significant reduction in both serum urea and serum phosphorus levels after eight weeks of oral-activated charcoal treatment. However, the other biomarkers were not affected by the treatment.

A separate published trial in Chinese patients with stage 3–4 CKD reported that oral activated charcoal effectively delays the onset of hyperphosphatemia in patients with chronic kidney disease, and OAC appears to delay the development of vascular calcifications in stage 3–4 CKD patients. In that study, the OAC group was given oral activated charcoal at 0.6–1.2 g each time, three times a day, taken with food.

A 2025 pilot randomized controlled trial of activated bamboo charcoal in CKD stage 3 patients over a 3-month period concluded that this study suggested that ABC significantly reduced uremic toxins and might have potential in improving eGFR in CKD stage 3 patients over a 3-month period.

Evidence characterization: The CKD evidence base currently consists of small RCTs with limited sample sizes and short follow-up periods. While individual biomarker outcomes are encouraging, the totality of evidence is preliminary and insufficient to establish a definitive clinical role. As of 2024, there have been a total of four clinical trials published on activated charcoal regarding kidney disease.

5.3 Cholestasis of Pregnancy (Intrahepatic Cholestasis)

The theoretical basis for activated charcoal in intrahepatic cholestasis of pregnancy (ICP) is its potential to adsorb bile acids within the intestinal lumen, interrupting their enterohepatic recirculation and thereby reducing circulating bile acid concentrations and associated pruritus. Scientists have studied activated charcoal to see if it helps with a condition during pregnancy called cholestasis. If you have this liver problem, bile doesn't flow as it should. The most common side effect is serious itching. The goal is to find out if charcoal would bind to the bile acids to help get rid of them. We'll need more research to know if it works.

A Cochrane systematic review (Gurung 2013, 26 trials involving 2,007 women) concluded: there is insufficient evidence to indicate if SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, Salvia, Yinchenghao decoction, Danxioling and Yiganling, or Yiganling alone or in combination are effective in treating women with intrahepatic cholestasis of pregnancy. An updated Cochrane review (2020) affirmed this finding: there is insufficient evidence to indicate that SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, YCHD, DXLP, Salvia, Yiganling alone or in combination are effective in treating women with cholestasis of pregnancy.

Evidence characterization: Very weak. Only a single small preliminary trial addressed activated charcoal specifically in ICP (Kaaja et al., Scand J Gastroenterol 1994), and the Cochrane reviews covering this topic have consistently found insufficient evidence to support its use for this indication.

5.4 Hypercholesterolemia

Some research shows that activated charcoal can keep your body from absorbing cholesterol. But study results are mixed on whether taking activated charcoal can lower your cholesterol levels. Early small controlled trials — including Neuvonen et al. (Eur J Clin Pharmacol 1989) and Park et al. (J Clin Pharmacol 1988) — examined activated charcoal against cholestyramine as a cholesterol-lowering agent, but the evidence base remains limited and inconsistent. So far, research studies don't agree about the effectiveness of taking activated charcoal by mouth to lower cholesterol levels in the blood.

Evidence characterization: Preliminary and inconsistent. No large high-quality RCTs exist. The theoretical mechanism — intestinal adsorption of bile acids and dietary cholesterol interrupting enterohepatic cholesterol recycling — is plausible but has not been substantiated by robust clinical evidence.

5.5 Intestinal Gas (Flatulence)

Some studies show that activated charcoal is effective in reducing intestinal gas, but other studies don't agree. It's too early to come to a conclusion on this. A study by Suarez et al. published in the American Journal of Gastroenterology (1999) found failure of activated charcoal to reduce the release of gases produced by the colonic flora. The evidence for this indication is mixed and insufficient to draw a conclusion.

Evidence characterization: Mixed, with at least one methodologically rigorous study demonstrating no benefit. The historical use of charcoal for digestive complaints (e.g., charcoal biscuits sold in 19th-century England) is well documented, but controlled clinical evidence is lacking or conflicting.

5.6 Teeth Whitening and Oral Hygiene

Activated charcoal has been widely incorporated into commercial toothpastes and dental powders marketed for whitening. A 2024 randomized controlled clinical trial concluded: based on the whitening effect and patient satisfaction, this controlled-randomized clinical evidence supports that the use of activated charcoal-based products should be discouraged.

The scientific evidence supporting its efficacy remains limited and contradictory. Some studies suggest minor improvements in tooth color, while others raise concerns about its abrasive potential and lack of effect on intrinsic stains. There is insufficient scientific evidence for this action and, as a result, it has been assumed that charcoal does not modify tooth color other than by an abrasive action similar to regular toothpastes. For this reason, some authors recommend this type of toothpaste only for color maintenance by delaying the recurrence of surface stains on tooth surfaces after tooth bleaching treatment.

It has been proposed that the high absorption capacity of activated charcoal may reduce the availability of fluoride ions in the toothpaste formulation, leading to a limited ability to remineralize tooth tissues and, as a consequence, lower resistance to caries and tooth decay.

Evidence characterization: Weak to negative. A published RCT discourages use. The American Dental Association does not recommend charcoal-based tooth whitening products, and concerns about enamel abrasion are noted in the peer-reviewed literature.

5.7 Wound Dressings and Topical Applications

Some research shows that using activated charcoal in bandages can help heal certain leg ulcers. It might also help stop the smells that come from infections. Other studies have had mixed results on whether charcoal can help with ulcers or bedsores. The clinical evidence for topical wound applications is limited and mixed; no large high-quality trials have established a definitive benefit.

Evidence characterization: Preliminary and mixed. The proposed mechanism — adsorption of malodorous volatile compounds and bacterial exotoxins — is mechanistically plausible but has not been confirmed by robust RCTs.

5.8 Hemoperfusion

The resulting biocompatible polymer-coated carbon is useful for hemoperfusion. Hemoperfusion is a treatment technique in which large volumes of the patient's blood are passed over an adsorbent substance in order to remove toxic substances from the blood. In clinical trials, polymer-coated carbons have achieved over 80% removal of toxins such as bilirubin and certain drug metabolites in a single pass. This is a specialist clinical application distinct from oral ingestion, used primarily in severe drug overdose or poisoning not amenable to oral decontamination.

6. Body Systems and Health Areas Associated with Activated Charcoal

• Gastrointestinal system: Primary locus of action for oral use; adsorbs toxins, drugs, and potentially bile acids and cholesterol in the intestinal lumen.
• Hepatic/biliary system: Investigated for interrupting enterohepatic recirculation of bile acids (cholestasis) and certain drugs.
• Renal system: Investigated as an intestinal adsorbent to reduce circulating uremic toxins (urea, indoxyl sulfate, phosphorus) in CKD.
• Cardiovascular system: Investigated tangentially through potential effects on cholesterol and uremic toxin-driven vascular calcification.
• Oral/dental: Used in toothpastes and dental powders, with evidence against efficacy for whitening and concerns about abrasion.
• Dermatological/wound care: Applied topically in activated charcoal wound dressings with preliminary evidence for odor control and limited evidence for healing.
• Circulatory system (extracorporeal): Polymer-coated activated charcoal columns used in hemoperfusion for removal of blood-borne toxins.

7. Dosage Forms and Dosages Reported in Studies

7.1 Acute Poisoning — Single-Dose Activated Charcoal (SDAC)

When used, an activated charcoal-to-drug ratio of approximately 10:1 is suggested. In pediatric patients with an unknown amount ingested, dosing is typically 1 to 2 g/kg. The initial dose may be combined with a cathartic agent, such as sorbitol, to improve palatability and gastrointestinal transit.

Ready-to-use clinical formulations include aqueous suspensions available in 15 g, 25 g, and 50 g doses, as well as formulations premixed with sorbitol.

7.2 Acute Poisoning — Multi-Dose Activated Charcoal (MDAC)

Dosing strategies of MDAC vary. The initial dosing is either a 10:1 ratio of activated charcoal to the toxin or 1 g/kg of body weight. Interval MDAC doses range from 0.25 to 0.5 g/kg of body weight every 1 to 6 hours in adults.

A simplified MDAC protocol for adults reported in the literature includes: a loading dose of 25 to 100 g, followed by repeat doses of 10 to 25 g of activated charcoal every two to four hours.

Due to the variability in proper dosing strategies and indications for MDAC administration, it would be reasonable to consult a regional toxicologist or Poison Control Center before initiating MDAC therapy.

7.3 Chronic Kidney Disease (as Reported in Published Trials)

The CKD trial by Rahman et al. (2023) used oral activated charcoal supplementation over an eight-week period in ESRD patients on hemodialysis, though the specific per-dose quantity was not specified in the available abstract. In the CKD trial by Tang et al. in Chinese stage 3–4 patients, the OAC group was given oral activated charcoal at 0.6–1.2 g each time, three times a day, taken with food.

7.4 Administration Route and Formulation Considerations

If activated charcoal is not premixed, a slurry can be made with activated charcoal in a 1:8 ratio of activated charcoal to a suitable liquid such as water, cola, or flavored syrups. Some cases have employed the continuous administration of activated charcoal through a nasogastric (NG) tube.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

As activated charcoal remains inactive in the gastrointestinal tract, no therapeutic index for systemic absorption is applicable. No significant toxicity from activated charcoal is expected as it is not absorbed systemically; however, adverse effects from its administration, such as emesis, aspiration, and bowel obstruction, may occur.

8.2 Gastrointestinal Adverse Effects

The adverse effects of activated charcoal in patients who have ingested poisons are difficult to measure because of the higher-than-usual dosage. With regular use, vomiting, constipation, diarrhea, nausea, urge to defecate, and anal irritation are all common. There have been a few reports — all in connection with repeated administration of high doses of activated charcoal — of either small intestinal (pseudo-)occlusion requiring surgical intervention or charcoal stercoliths perforating a loop of sigmoid colon.

Emesis is more common with rapid administration of activated charcoal, and the risk of emesis increases when sorbitol is added.

8.3 Pulmonary Aspiration (Most Serious Risk)

Pulmonary aspiration and resulting aspiration pneumonitis are the most concerning risks associated with the administration of activated charcoal. Aspiration from emesis and misplaced nasogastric tubes for activated charcoal administration can lead to severe respiratory compromise and even death. Therefore, an adequate airway assessment must occur before activated charcoal administration. In patients with a depressed level of consciousness, providers must consider the risk-to-benefit ratio of intubation for airway protection and the therapeutic benefits of activated charcoal.

A rare but serious complication is aspiration of charcoal leading to pulmonary failure, with a potentially fatal outcome. However, only isolated instances have been reported.

8.4 Formal Contraindications (AACT, 2005)

A position statement from the American Academy of Clinical Toxicology (AACT) in 2005 lists the following as contraindications and relative contraindications for activated charcoal use: patients with an unprotected airway (i.e., a depressed level of consciousness) without endotracheal intubation; if activated charcoal use is likely to increase the risk and severity of aspiration of a toxin (hydrocarbons with high aspiration potentials); and when the threat of GI perforation or hemorrhage is high secondary to medical conditions or recent surgery. MDAC is relatively contraindicated if decreased peristalsis is likely to occur from the substance ingested (opioids or anticholinergics). If these patients receive MDAC, they should be monitored closely for the development of obstruction or potential aspiration.

8.5 Drug Interactions — Broad Non-Selectivity

Activated charcoal's adsorptive mechanism is fundamentally non-selective, which is both its clinical strength (broad toxin binding) and its most significant limitation in pharmacotherapy settings.

Activated charcoal may reduce the absorption and therapeutic effect of coadministered medications, including propranolol, rifampin, phenobarbital, and other orally administered agents.

Charcoal isn't a discriminating detoxifier; it will adsorb vitamins, minerals, and medications alike. This includes antidepressants, birth control pills, over-the-counter painkillers, anti-epileptics, beta blockers and anti-arrhythmic drugs, medications for diabetes, and even steroids from asthma inhalers.

A preclinical study published in PubMed quantified the food-moderated interaction between activated charcoal and phenobarbital: activated charcoal is known to decrease the intestinal absorption of co-administered drug by adsorption. The extent of this drug-drug interaction (DDI) is attenuated by food intake. Under fasted conditions, activated charcoal significantly decreased the AUC of phenobarbital by 45.2%. When a standard breakfast or high-fat meal was fed, this DDI was reduced to 28.3% and 18.0%, respectively.

8.6 Nutrient Absorption and Chronic Supplement Use

The Association of Food and Drug Officials has asked the FDA to review the use of activated charcoal in foods and beverages because of several safety concerns. Individuals who regularly consume products containing activated charcoal may be at risk for reduced effectiveness of routine medications, nutrient deficiencies related to activated charcoal's binding to vitamins, minerals, and antioxidants, and adverse effects such as constipation.

Activated charcoal can bind to many different substances in your stomach. This prevents your body from absorbing these substances, which may include nutrients. If you regularly use activated charcoal supplements and also have malabsorption syndrome, you may be at a higher risk for nutrient deficiencies over time.

8.7 Pregnancy and Lactation

It is not known if or how activated charcoal could affect pregnancy or harm an unborn baby. It is not known if activated charcoal passes into breast milk. In emergency poisoning contexts, the benefit-risk balance generally favors use when a life-threatening toxin has been ingested and the standard contraindications do not apply. Activated charcoal is used in acute poisoning emergencies in pregnancy, but its safety and efficacy for non-emergency uses in pregnancy have not been established.

8.8 Fluoride Reduction in Dental Products

It has been proposed that the high absorption capacity of activated charcoal may reduce the availability of fluoride ions in the toothpaste formulation, leading to a limited ability to remineralize tooth tissues and, as a consequence, lower resistance to caries and tooth decay.

References

• Zellner T, et al. "The Use of Activated Charcoal to Treat Intoxications." Deutsches Ärzteblatt International, 2019. PMC6620762.
• Silberman J, Galuska MA, Taylor A. "Activated Charcoal." StatPearls. NCBI Bookshelf, NIH (updated April 2023).
• Jürgens G, et al. "The effect of activated charcoal on drug exposure following intravenous administration: A meta-analysis." PubMed, 2021.
• Olson KR, et al. "Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose." Clinical Toxicology, 2021. PubMed 34424785.
• Therapeutic Effectiveness and Safety of Activated Charcoal in Poisoning Management in Emergency Settings: A Systematic Review and Meta-analysis. ResearchGate, 2025.
• Rahman WK, et al. "Protective effect of activated charcoal against progression of chronic kidney disease: A randomized clinical study." Journal of Medicine and Life, 2023. PMC10719797.
• Tang, et al. "Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease." PMC6422957.
• Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in CKD patients: a pilot randomized controlled trial. PubMed 40093417, 2025.
• Gurung V, et al. "Interventions for treating cholestasis in pregnancy." Cochrane Database of Systematic Reviews, 2013.
• Ovadia C, et al. "Pharmacological interventions for treating intrahepatic cholestasis of pregnancy." PubMed 32716060, 2020.
• Protective effect of activated charcoal against progression of chronic kidney disease. PubMed 38107705.
• Whitening efficacy of activated charcoal-based products: A single-blind randomized controlled clinical trial. PubMed 38316199, 2024.
• Effect of 16% Carbamide Peroxide and Activated-Charcoal-Based Whitening Toothpaste on Enamel Surface Roughness in Bovine Teeth: An In Vitro Study. PMC9856117.
• Effectiveness of Activated Charcoal Toothpaste vs. 6% Hydrogen Peroxide Whitening Pen — An In Vitro Study. PMC12109725.
• Effects of food type on the extent of drug-drug interactions between activated charcoal and phenobarbital in rats. PubMed 31255507.
• Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. PMC2430417.
• Effect of pore size and morphology of activated charcoal prepared from midribs of Elaeis guineensis on adsorption of poisons. PMC6014264.
• Activated charcoal (medication). Wikipedia (references to primary sources).
• Activated carbon. Wikipedia (references to primary sources).
• The History of Activated Carbon — from ancient medicine to air pollution control. DEC Group.
• Medical Use of Activated Charcoal. Veterinary Medicine Extension, Washington State University, 2018.